Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bordetella pertussis antigens (acellular) (aP antigens)
- Target
- aP antigens
- Molecular classification
- Protein, Toxin, Adhesin, Surface Antigen
01
Overview
Purified components of the Bordetella pertussis bacterium used in acellular pertussis vaccines (aP). These antigens, including Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA), Pertactin (PRN), and Fimbriae types 2 and 3 (FIM2/3), are designed to induce immunity against whooping cough. They stimulate both antibody-mediated and cell-mediated immune responses, targeting secreted toxins or surface proteins to neutralize their activity or prevent bacterial adhesion. However, aP-induced immunity differs from natural infection, potentially leading to waning immunity and the emergence of strains lacking certain vaccine-included proteins. Newer vaccines may include adenylate cyclase toxin.
- Other names
- Pertussis Toxin (PT)Filamentous Hemagglutinin (FHA)Pertactin (PRN)Fimbriae types 2 and 3 (FIM2/3)PTFHAPRNFIM2/3
02
Mechanism of action
N/A
03
Biological functions
Adhesion to respiratory epithelial cellsImmune response inductionToxin activityBacterial colonizationResistance to neutrophil-mediated clearanceImmunomodulation
04
Disease associations
Whooping coughBordetella pertussis infection
05
Safety considerations
Waning immunity over timeEmergence of pertactin-deficient strainsTh1/Th2 response instead of Th17
06
Interacting drugs
None (these are vaccine components, not drug targets)
07
Biomarkers
Antibody titers against PTAntibody titers against FHAAntibody titers against PRNAntibody titers against FIM2/3Cell-mediated immunity (proliferation of immune cells stimulated by B. pertussis antigens)
Beyond the preview
Go deeper on Bordetella pertussis antigens (acellular) (aP antigens).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bordetella pertussis antigens (acellular) (aP antigens).